Optimal use of β-blockers in high-risk hypertension: A guide to dosing equivalence

References

• CherryDKWoodwellDANational Ambulatory Medical Care Survey: 2000 summaryAdv Data2002328132
   PubMedGoogle Scholar
• Hypertension in America: A national readingAm J Manag Care20051113 SupplS383S385
   PubMed Web of Science ®Google Scholar
• OngKLCheungBMManYBLauCPLamKSPrevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004Hypertension20074916975
   PubMed Web of Science ®Google Scholar
• MoserMEvolution of the treatment of hypertension from the 1940s to JNC VAm J Hypertens19971032S8S
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHRSeventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension20034261206125214656957
   PubMed Web of Science ®Google Scholar
• BakrisGLThe importance of blood pressure control in the patient with diabetesAm J Med2004116Suppl 5A30S38S15019861
   PubMed Web of Science ®Google Scholar
• Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 UK Prospective Diabetes Study GroupBMJ19983177160703713
   PubMed Web of Science ®Google Scholar
• Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study GroupBMJ19983177160713720
   PubMed Web of Science ®Google Scholar
• TorreJJBloomgardenZTDickeyRAAmerican Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of hypertensionEndocr Pract2006122193222
   PubMedGoogle Scholar
• American Diabetes AssociationStandards of medical care in diabetesDiabetes Care200528Suppl 1S4S36
   PubMedGoogle Scholar
• BakrisGLWilliamsMDworkinLPreserving renal function in adults with hypertension and diabetes: A consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working GroupAm J Kidney Dis200036364666110977801
   PubMed Web of Science ®Google Scholar
• DoroodchiHAbdolrasulniaMFosterJAKnowledge and attitudes of primary care physicians in the management of patients at risk for cardiovascular eventsBMC Fam Pract2008942
   PubMed Web of Science ®Google Scholar
• SaydahSHFradkinJCowieCCPoor control of risk factors for vascular disease among adults with previously diagnosed diabetesJAMA20042913335342
   PubMed Web of Science ®Google Scholar
• BlackHRElliottWJNeatonJDBaseline characteristics and early blood pressure control in the CONVINCE trialHypertension20013711218
   PubMed Web of Science ®Google Scholar
• Cooper-DeHoffRMHandbergEMCohenJCharacteristics of contemporary patients with hypertension and coronary artery diseaseClin Cardiol2004271057157615553310
   PubMed Web of Science ®Google Scholar
• HajjarIKotchenTATrends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000JAMA20032902199206
   PubMed Web of Science ®Google Scholar
• SnowVWeissKBMottur-PilsonCThe evidence base for tight blood pressure control in the management of type 2 diabetes mellitusAnn Intern Med20031387587592
   PubMed Web of Science ®Google Scholar
• Arauz-PachecoCParrottMARaskinPTreatment of hypertension in adults with diabetesDiabetes Care200326Suppl 1S80S82
   PubMedGoogle Scholar
• HanssonLHednerTLund-JohansenPRandomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) studyLancet20003569227359365
   PubMed Web of Science ®Google Scholar
• BrownMJPalmerCRCastaigneAMorbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)Lancet20003569227366372
   PubMed Web of Science ®Google Scholar
• HanssonLLindholmLHNiskanenLEffect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trialLancet19993539153611616
   PubMed Web of Science ®Google Scholar
• CarlbergBSamuelssonOLindholmLHAtenolol in hypertension: Is it a wise choice?Lancet2004364944616841689
   PubMed Web of Science ®Google Scholar
• LawMRWaldNJMorrisJKJordanREValue of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trialsBMJ200332674041427
   PubMed Web of Science ®Google Scholar
• NeatonJDGrimmRHJrPrineasRJTreatment of Mild Hypertension StudyFinal results. Treatment of Mild Hypertension Study Research GroupJAMA19932706713724
   PubMed Web of Science ®Google Scholar
• MatersonBJRedaDJCushmanWCDepartment of Veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive AgentsAm J Hypertens199582189192
   PubMed Web of Science ®Google Scholar
• TseWYKendallMIs there a role for beta-blockers in hypertensive diabetic patients?Diabet Med1994112137144
   PubMed Web of Science ®Google Scholar
• FonarowGCManaging the patient with diabetes mellitus and heart failure: Issues and considerationsAm J Med2004116Suppl 5A76S88S
   PubMedGoogle Scholar
• BellDSUse of beta blockers in the patient with diabetesEndocrinologist2003132116123
   Google Scholar
• A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality resultsJAMA19822471217071714
   PubMed Web of Science ®Google Scholar
• CIBIS-II Investigators and CommitteesThe Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trialLancet19993539146913
   PubMed Web of Science ®Google Scholar
• DargieHJEffect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: The CAPRICORN randomised trialLancet2001357926613851390
   PubMed Web of Science ®Google Scholar
• Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research GroupJAMA20002831519671975
   PubMed Web of Science ®Google Scholar
• MajumdarSRBeta-blockers for the treatment of hypertension in patients with diabetes: Exploring the contraindication mythCardiovasc Drugs Ther1999135435439
   PubMed Web of Science ®Google Scholar
• HaenniALithellHTreatment with a beta-blocker with beta 2-agonism improves glucose and lipid metabolism in essential hypertensionMetabolism1994434455461
   PubMed Web of Science ®Google Scholar
• BakrisGLFonsecaVKatholiREMetabolic effects of carvedilol vs. metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trialJAMA20042921822272236
   PubMed Web of Science ®Google Scholar
• BristowMRMechanism of action of beta-blocking agents in heart failureAm J Cardiol19978011A26L40L
   PubMed Web of Science ®Google Scholar
• BristowMRBeta-adrenergic receptor blockade in chronic heart failureCirculation20001015558569
   PubMed Web of Science ®Google Scholar
• PackerMBeta-adrenergic blockade in chronic heart failure: Principles, progress, and practiceProg Cardiovasc Dis1998411 Suppl 13952
   PubMed Web of Science ®Google Scholar
• Poole-WilsonPASwedbergKClelandJGComparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): Randomised controlled trialLancet20033629377713
   PubMed Web of Science ®Google Scholar
• WikstrandJBerglundGTuomilehtoJBeta-blockade in the primary prevention of coronary heart disease in hypertensive patients. Review of present evidenceCirculation1991846 SupplVI93VI100
   PubMed Web of Science ®Google Scholar
• LindholmLHCarlbergBSamuelssonOShould beta blockers remain first choice in the treatment of primary hypertension? A meta-analysisLancet2005366949615451553
   PubMed Web of Science ®Google Scholar
• JacobSRettKWicklmayrMAgrawalBAugustinHJDietzeGJDifferential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: The carvedilol-metoprolol studyJ Hypertens1996144489494
   PubMed Web of Science ®Google Scholar
• GiuglianoDAcamporaRMarfellaRMetabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trialAnn Intern Med199712612955959
   PubMed Web of Science ®Google Scholar
• SchmidtACGrafCBrixiusKScholzeJBlood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus: The YESTONO studyClin Drug Investig20072712841849
   PubMed Web of Science ®Google Scholar
• McGillJBBakrisGLFonsecaVBeta-blocker use and diabetes symptom score: Results from the GEMINI studyDiabetes Obes Metab200793408417
   PubMed Web of Science ®Google Scholar
• PedersenMECockcroftJRThe vasodilatory beta-blockersCurr Hypertens Rep200794269277
   PubMed Web of Science ®Google Scholar
• StolwijkJAResponses to the thermal environmentFed Proc197736516551658
   PubMedGoogle Scholar
• MesserliFHGrossmanEBeta-blockers in hypertension: Is carvedilol different?Am J Cardiol2004939A7B12B
   PubMed Web of Science ®Google Scholar
• YiannakopoulouEPapadopulosJSCokkinosDVMountokalakisTDAdherence to antihypertensive treatment: A critical factor for blood pressure controlEur J Cardiovasc Prev Rehabil2005123243249
   PubMedGoogle Scholar
• GrantRWDevitaNGSingerDEMeigsJBPolypharmacy and medication adherence in patients with type 2 diabetesDiabetes Care200326514081412
   PubMed Web of Science ®Google Scholar
• UbelPAJepsonCAschDAMisperceptions about beta-blockers and diuretics: A national survey of primary care physiciansJ Gen Intern Med2003181297798314687255
   PubMed Web of Science ®Google Scholar
• DahlofBDevereuxRBKjeldsenSECardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenololLancet200235993119951003
   PubMed Web of Science ®Google Scholar
• MatersonBJRedaDJCushmanWCSingle-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive AgentsN Engl J Med199332813914921
   PubMed Web of Science ®Google Scholar
• CroogSHLevineSTestaMAThe effects of antihypertensive therapy on the quality of lifeN Engl J Med19863142616571664
   PubMed Web of Science ®Google Scholar
• OgiharaTKuramotoKEffect of long-term treatment with antihypertensive drugs on quality of life of elderly patients with hypertension: A double-blind comparative study between a calcium antagonist and a diuretic. NICS-EH Study Group. National Intervention Cooperative Study in Elderly HypertensivesHypertens Res2000231333710737133
   PubMedGoogle Scholar
• ClaxtonAJCramerJPierceCA systematic review of the associations between dose regimens and medication complianceClin Ther200123812961310
   PubMed Web of Science ®Google Scholar
• Van WijkBLKlungelOHHeerdinkERde BoerARate and determinants of 10-year persistence with antihypertensive drugsJ Hypertens2005231121012107
   PubMed Web of Science ®Google Scholar
• Mena-MartinFJMartin-EscuderoJCSimal-BlancoFCarretero-AresJLArzua-MouronteDHerreros-FernandezVHealth-related quality of life of subjects with known and unknown hypertension: Results from the population-based Hortega studyJ Hypertens200321712831289
   PubMed Web of Science ®Google Scholar
• ChengJWKalisMMFeiferSPatient-reported adherence to guidelines of the Sixth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressurePharmacotherapy2001217828841
   PubMed Web of Science ®Google Scholar
• HulkaBSCasselJCKupperLLBurdetteJACommunication, compliance, and concordance between physicians and patients with prescribed medicationsAm J Public Health1976669847853
   PubMed Web of Science ®Google Scholar
• BurnierMMedication adherence and persistence as the cornerstone of effective antihypertensive therapyAm J Hypertens2006191111901196
   PubMed Web of Science ®Google Scholar
• BangaloreSParkarSGrossmanEMesserliFHA meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitusAm J Cardiol2007100812541262
   PubMed Web of Science ®Google Scholar
• AursnesIOsnesJBTveteIFGasemyrJNatvigBDoes atenolol differ from other beta-adrenergic blockers?BMC Clin Pharmacol200774
   PubMedGoogle Scholar
• TENORMIN® (atenolol) Tablets [Prescribing information]Wilmington, DEAstraZeneca Pharmaceuticals LP2008Available at: http://www.realmentalhealth.com/medications/tenormin.asp?view=print Accessed November 6, 2009.
   Google Scholar
• SarafidisPBogojevicZBastaEKirstnerEBakrisGLComparative efficacy of two different beta-blockers on 24-hour blood pressure controlJ Clin Hypertens (Greenwich)2008102112118
   PubMed Web of Science ®Google Scholar
• NeutelJMSchnaperHCheungDGGraettingerWFWeberMAAntihypertensive effects of beta-blockers administered once daily: 24-hour measurementsAm Heart J19901201166171
   PubMed Web of Science ®Google Scholar
• KohKKQuonMJHanSHDistinct vascular and metabolic effects of different classes of anti-hypertensive drugsInt J Cardiol201014017381
   PubMed Web of Science ®Google Scholar
• GuptaAKDahlofBDobsonJSeverPSWedelHPoulterNRDeterminants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial – blood pressure lowering arm and the relative influence of antihypertensive medicationDiabetes Care2008315982988
   PubMed Web of Science ®Google Scholar
• OlsenMHFossumEHoieggenALong-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudyJ Hypertens200523489189815775796
   PubMed Web of Science ®Google Scholar
• KendallMJMaxwellSRSandbergAWestergrenGControlled release metoprolol. Clinical pharmacokinetic and therapeutic implicationsClin Pharmacokinet1991215319330
   PubMed Web of Science ®Google Scholar
• LuckerPMooreGWieselgrenIOlofssonBBergstrandRPharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided dosesJ Clin Pharmacol1990302 SupplS17S27
   PubMed Web of Science ®Google Scholar
• Alternatives for metoprolol succinatePharmacist’s Letter/Prescriber’s Letter2009253250302
   Google Scholar
• MacCarthyEPBloomfieldSSLabetalol: A review of its pharmacology, pharmacokinetics, clinical uses and adverse effectsPharmacotherapy198334193219
   PubMed Web of Science ®Google Scholar
• VaronJTreatment of acute severe hypertension: Current and newer agentsDrugs2008683283297
   PubMed Web of Science ®Google Scholar
• PodymowTAugustPHypertension in pregnancyAdv Chronic Kidney Dis2007142178190
   PubMed Web of Science ®Google Scholar
• KaneJALabetalol in general practice: A reviewBr J Clin Pharmacol1982131 Suppl59S63S
   PubMedGoogle Scholar
• WallinJDWilsonDWinerNTreatment of severe hypertension with labetalol compared with methyldopa and furosemide. Results of a long-term, double-blind, multicenter trialAm J Med1983754A8794
   PubMed Web of Science ®Google Scholar
• CleophasTJAgrawalRLichtenthalAMakelWFiciFNationwide efficacy-safety study of nebivolol in mildly hypertensive patientsAm J Ther2006133192197
   PubMedGoogle Scholar
• Van BortelLMFiciFMascagniFEfficacy and tolerability of nebivolol compared with other antihypertensive drugs: A meta-analysisAm J Cardiovasc Drugs2008813544
   PubMed Web of Science ®Google Scholar
• Van NuetenLTaylorFRRobertsonJINebivolol vs. atenolol and placebo in essential hypertension: A double-blind randomised trialJ Hum Hypertens1998122135140
   PubMed Web of Science ®Google Scholar
• CockcroftJA review of the safety and efficacy of nebivolol in the mildly hypertensive patientVasc Health Risk Manag200736909917
   PubMedGoogle Scholar
• COREG CR® (carvedilol phosphate) Extended-release capsules [Prescribing information]Research Triangle Park, NCGlaxoSmithKline, Inc.2008Available at: http://us.gsk.com/products/assets/us_coregcr.pdf Accessed November 6, 2009.
   Google Scholar
• HendersonLSTeneroDMBaidooCAPharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertensionAm J Cardiol2006987A17L26L
   PubMed Web of Science ®Google Scholar
• PackerMLukasMATeneroDMBaidooCAGreenbergBHPharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarctionAm J Cardiol2006987A39L45L
   PubMed Web of Science ®Google Scholar
• WeberMASicaDATarkaEAIyengarMFleckRBakrisGLControlled-release carvedilol in the treatment of essential hypertensionAm J Cardiol2006987A32L38L
   PubMed Web of Science ®Google Scholar
• WeberMABakrisGLTarkaEAIyengarMFleckRSicaDAEfficacy of a once-daily formulation of carvedilol for the treatment of hypertensionJ Clin Hypertens (Greenwich)200681284084917170609
   PubMedGoogle Scholar
• TeneroDMHendersonLSBaidooCAPharmacokinetic properties of a new controlled-release formulation of carvedilolAm J Cardiol2006987A5L16L
   PubMed Web of Science ®Google Scholar
• FonarowGCProfile of carvedilol controlled-release: A new once-daily formulation of carvedilolExpert Opin Pharmacother200671825332546
   PubMed Web of Science ®Google Scholar